Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04054375 · ClinicalTrials.gov registry record · Phase 2

Weekly Steroids in Muscular Dystrophy

A Phase 2 study, sponsored by Northwestern University.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT04054375 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04054375, a Phase 2 study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and efficacy of oral weekly glucocorticoid steroids in patients with Becker Muscular Dystrophy (BMD), an inherited disorder in which patients experience weakness of the legs and pelvis, and Limb Girdle Muscular Dystrophy (LGMD), an inherited disorder in which patients experience progressive muscular weakness predominately in their hip and shoulders. The primary objective is safety which we the investigators will measure using laboratory testing and forced vital capacity (FVC), a breathing test that measures the strength of your lungs. The secondary objective is efficacy which will be measured by a change in MRI muscle mass, improved muscle performance, and quality of life. The investigators hypothesize that patients who receive oral weekly glucocorticoid steroids will have improviements in strength and quality of life compared to their baseline. Furthermore, the investigators anticipate that oral weekly glucocorticoid steroids will not have significant adverse impact on patients.

Interventions

  • DRUG Prednisone

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-07-01
Est. Completion 2022-03-01
Phase Phase 2

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT04054375

The ClinicalTrials.gov registry entry for NCT04054375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Prednisone is the first listed.

NCT04054375 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04054375 about?

NCT04054375 is a clinical study titled "Weekly Steroids in Muscular Dystrophy". The purpose of this study is to evaluate the safety and efficacy of oral weekly glucocorticoid steroids in patients with Becker Muscular Dystrophy (BMD), an inherited disorder in which patients experience weakness of the legs and pelvis, and Limb Girdle Muscular Dystrophy (LGMD), an inherited disord...

What is the current status of trial NCT04054375?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-07-01. Estimated completion is 2022-03-01.

What interventions are being tested in trial NCT04054375?

The interventions under investigation include: Prednisone (DRUG).

Who is sponsoring clinical trial NCT04054375?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.